Nephro-Urology Monthly

Published by: Kowsar

Antiplatelet Therapy in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions

Francesco Summaria 1 , * , Maria B. Giannico 1 , Giovanni P. Talarico 1 and Roberto Patrizi 1
Authors Information
1 Department of Cardiology-Policlinico Casilino, Catheter Laboratory, Rome, Italy
Article information
  • Nephro-Urology Monthly: July 01, 2015, 7 (4); e28099
  • Published Online: July 22, 2015
  • Article Type: Review Article
  • Received: February 21, 2015
  • Accepted: March 17, 2015
  • DOI: 10.5812/numonthly.28099

To Cite: Summaria F, Giannico M B, Talarico G P, Patrizi R. Antiplatelet Therapy in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions, Nephro-Urol Mon. 2015 ; 7(4):e28099. doi: 10.5812/numonthly.28099.

Copyright © 2015, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
  • 1. Haroun MK, Jaar BG, Hoffman SC, Comstock GW, Klag MJ, Coresh J. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol. 2003; 14(11): 2934-41[PubMed]
  • 2. Islam TM, Fox CS, Mann D, Muntner P. Age-related associations of hypertension and diabetes mellitus with chronic kidney disease. BMC Nephrol. 2009; 10: 17[DOI][PubMed]
  • 3. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298(17): 2038-47[DOI][PubMed]
  • 4. Ritz E, Bakris G. World Kidney Day: hypertension and chronic kidney disease. Lancet. 2009; 373(9670): 1157-8[DOI]
  • 5. Darlington A, Ferreiro JL, Ueno M, Suzuki Y, Desai B, Capranzano P, et al. Haemostatic profiles assessed by thromboelastography in patients with end-stage renal disease. Thromb Haemost. 2011; 106(1): 67-74[DOI][PubMed]
  • 6. Sanchez Perales MC, Vazquez E, Garcia Cortes MJ, Borrego FJ, Borrego J, Perez del Barrio P, et al. [Platelet antiaggregation and hemorrhagic risk in hemodialysis]. Nefrologia. 2002; 22(5): 456-62[PubMed]
  • 7. Di Minno G, Cerbone A, Usberti M, Cianciaruso B, Cortese A, Farace MJ, et al. Platelet dysfunction in uremia. II. Correction by arachidonic acid of the impaired exposure of fibrinogen receptors by adenosine diphosphate or collagen. J Lab Clin Med. 1986; 108(3): 246-52[PubMed]
  • 8. Moal V. Impaired expression of glycoproteins on resting and stimulated platelets in uraemic patients. Nephrol Dial Transpl. 2003; 18(9): 1834-41[DOI]
  • 9. Kaw D, Malhotra D. Platelet dysfunction and end-stage renal disease. Semin Dial. 2006; 19(4): 317-22[DOI][PubMed]
  • 10. Bonomini M, Dottori S, Amoroso L, Arduini A, Sirolli V. Increased platelet phosphatidylserine exposure and caspase activation in chronic uremia. J Thromb Haemost. 2004; 2(8): 1275-81[DOI][PubMed]
  • 11. Ando M, Iwata A, Ozeki Y, Tsuchiya K, Akiba T, Nihei H. Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients. Kidney Int. 2002; 62(5): 1757-63[DOI][PubMed]
  • 12. Irish A. Cardiovascular disease, fibrinogen and the acute phase response Associations with lipids and blood pressure in patients with chronic renal disease. Atherosclerosis. 1998; 137(1): 133-9[DOI]
  • 13. Mercier E, Branger B, Vecina F, Al-Sabadani B, Berlan J, Dauzat M, et al. Tissue factor coagulation pathway and blood cells activation state in renal insufficiency. Hematol J. 2001; 2(1): 18-25[DOI][PubMed]
  • 14. Catena C, Zingaro L, Casaccio D, Sechi LA. Abnormalities of coagulation in hypertensive patients with reduced creatinine clearance. Am J Med. 2000; 109(7): 556-61[DOI]
  • 15. Vaziri ND, Shah GM, Winer RL, Gonzales E, Patel B, Alikhani S, et al. Coagulation cascade, fibrinolytic system, antithrombin III, protein C and protein S in patients maintained on continuous ambulatory peritoneal dialysis. Thrombosis Res. 1989; 53(2): 173-80[DOI]
  • 16. Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, Van de Werf F, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol. 2005; 96(9): 1200-6[DOI][PubMed]
  • 17. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006; 114(8): 774-82[DOI][PubMed]
  • 18. Ndrepepa G, Berger PB, Mehilli J, Seyfarth M, Neumann FJ, Schomig A, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol. 2008; 51(7): 690-7[DOI][PubMed]
  • 19. Mehran R, Pocock SJ, Stone GW, Clayton TC, Dangas GD, Feit F, et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J. 2009; 30(12): 1457-66[DOI][PubMed]
  • 20. Authors/Task Force M, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014; 35(37): 2541-619[DOI][PubMed]
  • 21. Amsterdam EA, Wenger NK, Brindis RG, Casey DJ, Ganiats TG, Holmes DJ, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 130(25): 2354-94[DOI][PubMed]
  • 22. Chertow GM, Normand SL, McNeil BJ. "Renalism": inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency. J Am Soc Nephrol. 2004; 15(9): 2462-8[DOI][PubMed]
  • 23. Hemmelgarn BR, Southern D, Culleton BF, Mitchell LB, Knudtson ML, Ghali WA, et al. Survival after coronary revascularization among patients with kidney disease. Circulation. 2004; 110(14): 1890-5[DOI][PubMed]
  • 24. Reddan DN, Szczech LA, Tuttle RH, Shaw LK, Jones RH, Schwab SJ, et al. Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease. J Am Soc Nephrol. 2003; 14(9): 2373-80[PubMed]
  • 25. Chang TI, Shilane D, Kazi DS, Montez-Rath ME, Hlatky MA, Winkelmayer WC. Multivessel coronary artery bypass grafting versus percutaneous coronary intervention in ESRD. J Am Soc Nephrol. 2012; 23(12): 2042-9[DOI][PubMed]
  • 26. Tsai TT, Messenger JC, Brennan JM, Patel UD, Dai D, Piana RN, et al. Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry-CMS claims database. J Am Coll Cardiol. 2011; 58(18): 1859-69[DOI][PubMed]
  • 27. Shenoy C, Boura J, Orshaw P, Harjai KJ. Drug-eluting stents in patients with chronic kidney disease: a prospective registry study. PLoS One. 2010; 5(11)[DOI][PubMed]
  • 28. Arulkumaran N, Annear NM, Singer M. Patients with end-stage renal disease admitted to the intensive care unit: systematic review. Br J Anaesth. 2013; 110(1): 13-20[DOI][PubMed]
  • 29. Keltai M, Tonelli M, Mann JF, Sitkei E, Lewis BS, Hawken S, et al. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J Cardiovasc Prev Rehabil. 2007; 14(2): 312-8[DOI][PubMed]
  • 30. Small DS, Wrishko RE, Ernest Ii CS, Ni L, Winters KJ, Farid NA, et al. Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease. J Clin Pharm Ther. 2009; 34(5): 585-94[DOI]
  • 31. James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010; 122(11): 1056-67[DOI][PubMed]
  • 32. Capodanno D, Angiolillo DJ. Antithrombotic therapy in patients with chronic kidney disease. Circulation. 2012; 125(21): 2649-61[DOI][PubMed]
  • 33. Bellemain-Appaix A, O'Connor SA, Silvain J, Cucherat M, Beygui F, Barthelemy O, et al. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. JAMA. 2012; 308(23): 2507-16[DOI][PubMed]
  • 34. Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013; 369(11): 999-1010[DOI][PubMed]
  • 35. Montalescot G, van 't Hof AW, Lapostolle F, Silvain J, Lassen JF, Bolognese L, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014; 371(11): 1016-27[DOI][PubMed]
  • 36. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. 2005; 26(8): 804-47[DOI][PubMed]
  • 37. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005; 353(22): 2373-83[DOI][PubMed]
  • 38. Patrono C, Andreotti F, Arnesen H, Badimon L, Baigent C, Collet JP, et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J. 2011; 32(23): 2922-32[DOI][PubMed]
  • 39. Collaboration AT. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324(7329): 71-86[DOI]
  • 40. Summaria F, Romagnoli E, De Luca L, Mustilli M, Pagnanelli A. Feasibility and safety of transradial approach and bivalirudin treatment in elderly patients undergoing early invasive strategy for ACS: 'The OLDER Research Project' preliminary study. J Cardiovasc Med (Hagerstown). 2012; 13(5): 351-2[DOI][PubMed]
  • 41. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation. 2008; 118(16): 1626-36[DOI][PubMed]
  • 42. Current-Oasis Investigators , Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010; 363(10): 930-42[DOI][PubMed]
  • 43. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11): 1045-57[DOI][PubMed]
  • 44. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357(20): 2001-15[DOI][PubMed]
  • 45. Long-term results of prospective randomised study of coronary artery bypass surgery in stable angina pectoris. European Coronary Surgery Study Group. Lancet. 1982; 2(8309): 1173-80[PubMed]
  • 46. Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. The Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group. N Engl J Med. 1984; 311(21): 1333-9[DOI][PubMed]
  • 47. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009; 373(9665): 723-31[DOI]
  • 48. Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation. 2010; 122(21): 2131-41[DOI][PubMed]
  • 49. Bellemain-Appaix A, Brieger D, Beygui F, Silvain J, Pena A, Cayla G, et al. New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis. J Am Coll Cardiol. 2010; 56(19): 1542-51[DOI][PubMed]
  • 50. Erlinge D, Ten Berg J, Foley D, Angiolillo DJ, Wagner H, Brown PB, et al. Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial. J Am Coll Cardiol. 2012; 60(20): 2032-40[DOI][PubMed]
  • 51. Kamoi D, Ishii H, Takahashi H, Aoyama T, Toriyama T, Tanaka M, et al. Sirolimus- vs. paclitaxel-eluting stent to coronary intervention in dialysis patients. Int J Cardiol. 2013; 165(3): 533-6[DOI][PubMed]
  • 52. Sardi GL, Loh JP, Torguson R, Laynez-Carnicero A, Kitabata H, Xue Z, et al. Drug-eluting stents in patients on chronic hemodialysis: paclitaxel-eluting stents vs. limus-eluting stents. Cardiovasc Revasc Med. 2014; 15(2): 86-91[DOI][PubMed]
  • 53. Valgimigli M, Borghesi M, Tebaldi M, Vranckx P, Parrinello G, Ferrari R, et al. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). Eur Heart J. 2013; 34(12): 909-19[DOI][PubMed]
  • 54. Silber S, Kirtane AJ, Belardi JA, Liu M, Brar S, Rothman M, et al. Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. Eur Heart J. 2014; 35(29): 1949-56[DOI][PubMed]
  • 55. Urban P, Abizaid A, Chevalier B, Greene S, Meredith I, Morice MC, et al. Rationale and design of the LEADERS FREE trial: A randomized double-blind comparison of the BioFreedom drug-coated stent vs the Gazelle bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy. Am Heart J. 2013; 165(5): 704-9[DOI][PubMed]
  • 56. Chang TI, Montez-Rath ME, Shen JI, Solomon MD, Chertow GM, Winkelmayer WC. Thienopyridine use after coronary stenting in low income patients enrolled in medicare part D receiving maintenance dialysis. J Am Heart Assoc. 2014; 3(5)[DOI][PubMed]
  • 57. Park SH, Kim W, Park CS, Kang WY, Hwang SH, Kim W. A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol. 2009; 104(9): 1292-5[DOI][PubMed]
  • 58. Morel O, El Ghannudi S, Jesel L, Radulescu B, Meyer N, Wiesel ML, et al. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. J Am Coll Cardiol. 2011; 57(4): 399-408[DOI][PubMed]
  • 59. Htun P, Fateh-Moghadam S, Bischofs C, Banya W, Muller K, Bigalke B, et al. Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention. J Am Soc Nephrol. 2011; 22(4): 627-33[DOI][PubMed]
  • 60. Alexopoulos D, Panagiotou A, Xanthopoulou I, Komninakis D, Kassimis G, Davlouros P, et al. Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. J Thromb Haemost. 2011; 9(12): 2379-85[DOI][PubMed]
  • 61. Alexopoulos D, Xanthopoulou I, Plakomyti TE, Goudas P, Koutroulia E, Goumenos D. Ticagrelor in clopidogrel-resistant patients undergoing maintenance hemodialysis. Am J Kidney Dis. 2012; 60(2): 332-3[DOI][PubMed]
  • 62. Jeong KH, Cho JH, Woo JS, Kim JB, Kim WS, Lee TW, et al. Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study. Am J Kidney Dis. 2015; 65(6): 916-24[DOI][PubMed]
  • 63. Herzog CA, Ma JZ, Collins AJ. Long-term outcome of renal transplant recipients in the United States after coronary revascularization procedures. Circulation. 2004; 109(23): 2866-71[DOI][PubMed]
  • 64. Summaria F, Manca Di Villahermosa S, Tedesco M, Lonzi M, Colarieti G, Chamoun MG, et al. Cardiovascular outcome in asymptomatic hemodialysis patients submitted to aggressive medical therapy: results of a four-year follow-up. Minerva Cardioangiol. 2011; 59(2): 121-6[PubMed]
Readers' Comments